Retinoid related molecules: New promises against lung and breast cancer

Expert Opinion on Investigational Drugs

Volumn 7, Issue 4, 1998, Pages 601-606

  Pfahl, Magnus ^a  

^a SIDNEY KIMMEL CANCER CENTER   (United States)

Author keywords

anticancer drugs; breast cancer; lung cancer; retinoid related molecules; RXR selective retinoids

Indexed keywords

EID: 0003202588     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.7.4.601     Document Type: Article

References (28)

1. SPORN MB, ROBERTS AB, GOODMAN OS: The Retinoids:Biology, Chemistry and Medicine (Second Edition). Raven Press, Ltd, New York, NY (1994).
2. CASTAIGNE S, CHOMIENNE C, DANIEL MT et al.: All-trans-retinoic acid as a differentiation therapy for acute promyelocytic leukemia. Blood (1990) 76: 1704–1709.
3. HUANG ME, YE YC, CHEN SR et al.: Use of all-trans-ret-inoic acid in the treatment of acute promyelocytic leu-kemia. Blood (1988) 72: 567–572.
4. PFAHL M, APFEL R, BENDIK I et al.: Nuclear retinoid re-ceptors and their mechanism of action. In: Vitamins and Hormones Vol. 49. Litwac G (Ed.), Academic Press, Inc., Orlando, FL, USA (1994): 327–382.
5. MANGELSDORF DJ, UMESONO K, EVANS R: The retinoid receptors. In: The Retinoids (Second Edition), Sporn MB, Roberts AB, Goodman DS (Eds.), Academic Press, Inc., Or-lando, FL, USA (1994): 319–349.
6. CHAMBON P: The retinoid signaling pathway: molecu-lar and genetic analyses. Semin. Cell Biol. (1994) 5: 115–125.
7. LA VISTA-PICARD N, HOBBS PD, PFAHL M et al.: Thereceptor-DNA complex determines the retinoid re-sponse: a mechanism for the diversafication of theligand signal. Mol Cell Biol (1996) 16: 4137–4146.
8. LEHMANN JM, JONG L, FANJUL A et al.: Retinoids selec-tive for retinoid X receptor response pathways. Science (1992) 258: 1944–1946.
9. ZHANG XK, LEHMANN J, HOFFMANN B et al.: Homodi-mer formation of retinoid X receptor induced by 9-cis retinoic acid. Nature (1992) 358: 587–591.
10. YANGYEN HF, ZHANG XK, GRAUPNER G et al.: Antago-nism between retinoic acid receptors and AP-1: impli-cation for tumor promotion and inflammation. New Biol. (1991) 3: 1206–1219.
11. PFAHL M: Nuclear receptor/AP-1 interaction. Endocri-nol. Rev. (1993) 14 (5): 651–658.
12. KLIEWER SA, LERNHARD JM, WILLSON TM et al.: A prosta-glandin J2 metabolite binds peroxisome proliferator-activated receptor y and promotes adipocyte differen-tiation. Cell (1995) 83: 813–819.
13. FORMAN BM, TONTONOZ P, CHEN J et al.: 15-deoxy-Al2,14-prostaglandin J2 is a ligand for the adi-pocyte determination factor PPARy. Cell (1995) 83: 803–812.
14. FORMAN BM, GOODE E, CHEN J et al.: Identification of a nuclear receptor that is activated by farnesol metabo-lites. Cell (1995) 81: 687–693.
15. KLIEWER SA, MOORE JT, WADE L et al.: An orphan nu-clear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell (1998) 92: 1–20.
16. GRAUPNER G, MALLE G, MAIGNAN J et al.: 6'-Substituted naphthalene-2-carboxylic acid analogs, a new class of retinoic acid receptor subtype-specific ligand. Bio-chem. Biophys. Res. Commun. (1991) 179: 1554–1561.
17. LEHMANN JM, DAWSON MI, HOBBS PD et al.: Identifica-tion of retinoids with nuclear receptor subtype-selective activities. Cancer Res. (1991) 51: 4804–4809.
18. FANJUL AN, DELTA D, PIEROTTI MA et al.: A novel class of retinoids with selective anti-AP-1 activity exhibit anti-proliferative activity. Nature (1994) 372: 107–111.
19. LU XP, FANJUL AN, PICARD N et al.: Novel retinoid-related molecules as apoptosis inducers and effective inhibitors of human lung cancer cells in vivo. Nature Medicine. (1997) 3: 686–690.
20. MUKHERJEE R, DAVIES PJA, CROMBIE DL et al: Sensitiza-tion of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature (1997) 386: 407–410.
21. PIEDRAFITA FJ, PFAHL M: Retinoid-induced apoptosisand Spl cleavage occur independently of transcrip-tion and require caspase activation. Mol. Cell Biol. (1997) 17: 6348–6358.
22. JORDAN VC: Studies on the estrogen receptor in breastcancer-20 years as a target for the treatment and prevention of cancer. Third Annual William I. McGuire Memorial Lecture. Cancer Res. Treat. (1995) 36: 267–285.
23. FISHER B, DIGNAM J, BRYANT J et al: Five versus morethan five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J. Natl. Cancer Inst. (1996) 88: 1529–1542.
24. FISHER B: Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients. J. Clin. On-col. (1996) 14: 1027–1039.
25. JORDAN VC: A current view of tamoxifen for the treat-ment and prevention of breast cancer. Fourteenth Gad-dum Memorial Lecture. Br. J. Pharmacol. (1993) 110: 507–517.
26. MILLER VA, BENEDETTI FM, RIGAS JR et al.: Initial clini-cal trial of a selective retinoid X receptor ligand, LGD1069. J. Gun. Oncol. (1997) 15: 790–795.
27. BISCHOFF ED, GOTTARDIS MM, MOON TE et al.: Beyondtamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGREITN) causes complete regression of mammary carcinoma. Cancer Res. (1998) 58: 479–484.
28. HSU JY, PFAHL M: ET-1 expression and growth inhibi-tion of prostate cancer cells: a retinoid target with novel specificity. Mol. Cell Biol. (1998). (Submitted.)